Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/112788
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors
Author: Jonker, D.
Rosen, L.
Sawyer, M.
de Braud, F.
Wilding, G.
Sweeney, C.
Jayson, G.
McArthur, G.
Rustin, G.
Goss, G.
Kantor, J.
Velasquez, L.
Syed, S.
Mokliatchouk, O.
Feltquate, D.
Kollia, G.
Nuyten, D.
Galbraith, S.
Citation: Annals of Oncology, 2011; 22(6):1413-1419
Publisher: Oxford University Press
Issue Date: 2011
ISSN: 0923-7534
1569-8041
Statement of
Responsibility: 
D. J. Jonker, L. S. Rosen, M. B. Sawyer, F. de Braud, G. Wilding, C. J. Sweeney, G. C. Jayson, G. A. McArthur, G. Rustin, G. Goss, J. Kantor, L. Velasquez, S. Syed, O. Mokliatchouk, D. M. Feltquate, G. Kollia, D. S. A. Nuyten, S. Galbraith
Abstract: Background: This study was designed to determine the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of brivanib in patients with advanced/metastatic solid tumors. Patients and methods: Ninety patients enrolled in this two-part, phase I open-label study of oral brivanib alaninate. The primary objectives of this study were (in part A) dose-limiting toxicity, maximum tolerated dose (MTD) and the lowest biologically active dose level and (in part B) the optimal dose/dose range. The secondary objectives of this study were preliminary evidence of antitumor activity, PK and PD. Results: Across part A (open-label dose escalation and MTD) and part B (open-label dose optimization), 68 patients received brivanib alaninate. Brivanib demonstrated a manageable toxicity profile at doses of 180–800 mg. Most toxic effects were mild. Systemic exposure of the active moiety brivanib increased linearly ≤1000 mg/day. The MTD was 800 mg/day. Forty-four patients were treated at the MTD: 20 with 800 mg continuously, 11 with 800 mg intermittently and 13 with 400 mg b.i.d. doses. Partial responses were confirmed in two patients receiving brivanib ≥600 mg. Dynamic contrast-enhanced magnetic resonance imaging demonstrated statistically significant decreases in parameters reflecting tumor vascularity and permeability after multiple doses in the 800-mg continuous q.d. and 400-mg b.i.d. dose cohorts. Conclusion: In patients with advanced/metastatic cancer, brivanib demonstrates promising antiangiogenic and antitumor activity and manageable toxicity at doses ≤800 mg orally q.d., the recommended phase II study dose.
Keywords: Antiangiogenesis; brivanib; fibroblast growth factor; vascular endothelial growth factor
Rights: © The Author 2010. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved.
RMID: 0030047851
DOI: 10.1093/annonc/mdq599
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.